Use of Andrographis paniculata (Burm.f.) Wall. ex Nees and risk of pneumonia in hospitalised patients with mild coronavirus disease 2019: A retrospective cohort study
Jeeranan Tanwettiyanont, Napacha Piriyachananusorn, Lilit Sangsoi, Benjawan Boonsong, Chamlong Sunpapoa, Patcharawan Tanamatayarat, Nat Na-Ek, Sukrit Kanchanasurakit
Frontiers in Medicine, doi:10.3389/fmed.2022.947373
Background: Andrographis paniculata (Burm.f.) Wall. ex Nees (AP) has been widely used in Thailand to treat mild COVID-19 infections since early 2020; however, supporting evidence is scarce and ambiguous. Thus, this study aimed to examine whether the use of AP is associated with a decreased risk of pneumonia in hospitalised mild COVID-19 patients.
Materials and methods: We collected data between March 2020 and August 2021 from COVID-19 patients admitted to one hospital in Thailand. Patients whose infection was confirmed by real-time polymerase chain reaction, had normal chest radiography and did not receive favipiravir at admission were included and categorised as either AP (deriving from a dried and ground aerial part of the plant), given as capsules with a total daily dose of 180 mg andrographolide for 5 days or standard of care. They were followed for pneumonia confirmed by chest radiography. Multiple logistic regression was used for the analysis controlling for age, sex, diabetes, hypertension, statin use, and antihypertensive drug use.
Ethics statement The studies involving human participants were reviewed and approved by the Ethical Committee for clinical research of Phrae Hospital approved this study (no. 70/2564). Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.
Author contributions JT, SK, and NN-E conceptualised the study objectives, designed and collected the data, contributed to the literature review, data cleaning, data analyses, and interpretation of the findings. JT prepared an initial manuscript. NN-E further developed subsequent manuscripts. SK, PT, NP, LS, BB, and CS critically revised the initial manuscript. All authors contributed to manuscript revision, read, and approved the submitted version.
Conflict of interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's note All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/..
References
Dai, Chen, Chai, Zhao, Wang et al., Overview of pharmacological activities of Andrographis paniculata and its major compound andrographolide, Crit Rev Food Sci Nutr,
doi:10.1080/10408398.2018.1501657Enmozhi, Raja, Sebastine, Joseph, Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach, J Biomol Struct Dyn,
doi:10.1080/07391102.2020.1760136Hossain, Urbi, Karuniawati, Mohiuddin, Qrimida et al., Andrographis paniculata (Burm. f.) wall. ex nees: an updated review of phytochemistry, antimicrobial pharmacology, and clinical safety and efficacy, Life,
doi:10.3390/life11040348Hossain, Urbi, Sule, Rahman, None
Jara, Undurraga, González, Paredes, Fontecilla et al., Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile, N Engl J Med,
doi:10.1056/NEJMoa2107715Karbwang, Bangchang, Repurposed drugs for COVID-19 treatment, J Thai Trad Alt Med
Phumiamorn, Sapsutthipas, Pruksakorn, Trisiriwanich, In vitro Study on Antiviral Activity of Andrographis paniculata against COVID-19
Rajagopal, Varakumar, Baliwada, Byran, Activity of phytochemical constituents of Curcuma longa (turmeric) and Andrographis paniculata against coronavirus (COVID-19): an in silico approach, Futur J Pharm Sci,
doi:10.1186/s43094-020-00126-xRattanaraksa, Khempetch, Poolwiwatchaikool, Nimitvilai, Loatrakul et al., The efficacy and safety of Andrographis paniculata extract for treatment of COVID-19 patients with mild symptoms, Nakhonpathom hospital. Reg 4-5 Med J
Sa-Ngiamsuntorn, Suksatu, Pewkliang, Thongsri, Kanjanasirirat et al., Anti-SARS-CoV-2 activity of Andrographis paniculata extract and its major component andrographolide in human lung epithelial cells and cytotoxicity evaluation in major organ cell representatives, J Nat Prod,
doi:10.1021/acs.jnatprod.0c01324Schumann, Heigl, Rohrbach, Sheriff, Wagner et al., A report on the first 7 sequential patients treated within the C-reactive protein apheresis in COVID (CACOV) registry, Am J Case Rep,
doi:10.12659/AJCR.935263Vandenbroucke, Elm, Altman, Gøtzsche, Mulrow et al., Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration, PLoS Med,
doi:10.1016/j.ijsu.2014.07.014Wanaratna, Leethong, Inchai, Chueawiang, Sriraksa et al., Efficacy and safety of Andrographis paniculata extract in patients with mild COVID-19: a randomized controlled trial (version 3). medRxiv,
doi:10.1101/2021.07.08.21259912Worakunphanich, Thavorncharoensap, Youngkong, Thadanipon, Thakkinstian, Safety of Andrographis paniculata: a systematic review and meta-analysis, Pharmacoepidemiol Drug Saf,
doi:10.1002/pds.5190Zeng, Wei, Zhou, Yuan, Lei et al., Andrographolide: a review of its pharmacology, pharmacokinetics, toxicity and clinical trials and pharmaceutical researches, Phyther Res,
doi:10.1002/ptr.7324Zhang, Lv, Zhou, Xie, Xu et al., Efficacy and safety of Xiyanping injection in the treatment of COVID-19: a multicenter, prospective, open-label and randomized controlled trial, Phytother Res,
doi:10.1002/ptr.7141
